

The Shift to Precision: Why MRI/Ultrasound Fusion is the New Gold Standard

Published Date: 05/25/2026



Joseph Ferrer
Clinical Education Specialist
ForTec Medical

Aligning with Excellence: Why AUA and NCCN Guidelines Now Prioritize MRI-Fusion

Prostate cancer detection has gone through a major transformation. MRI/ultrasound fusion biopsy is leading the shift and is now reflected in the major AUA and NCCN guidelines. By combining high resolution MRI data with real time ultrasound guidance, clinicians can target suspicious lesions with great accuracy. This advancement is improving patient outcomes, reducing unnecessary procedures, and strengthening diagnostic confidence.

The Diagnostic Gap

Traditional systematic prostate biopsies often miss clinically significant cancers. Without visual guidance, physicians often need to take more cores, thus increasing procedure time, patient discomfort, and complication risk.

The Impact

Missed or delayed diagnoses can lead to progression of clinically significant cancer, while false positives and repeat biopsies drive up costs, stress patients, and strain clinical workflow. Hospitals need a method that improves accuracy while reducing unnecessary procedures and complications.

Integrating MRI-Ultrasound Fusion: The UroNav Advantage

ForTec has been a leader in MRI/ultrasound fusion biopsy support since 2015, completing over **100,000 cases** with the UroNav fusion system. Our Certified Technology Specialists use Fusion technology overlays of MRI-identified lesions onto live ultrasound, enabling targeted sampling of areas most likely to harbor clinically significant disease (Gleason ≥ 7). This technique improves cancer detection and supports more confident clinical decision making.



Operational Benefits for Hospitals and Imaging Centers

- **Fewer unnecessary biopsies** thanks to precise lesion targeting.
- **Reduced complications** compared to non-targeted repeat procedures.
- **Better treatment planning** through 3D mapping, particularly for lesions in difficult-to-access regions.
- **No burden of ownership** – ForTec manages equipment, service, and operational support.
- **Consistent access to trained clinical specialists** to enhance workflow efficiency.

UroNav On-Demand: Specialized Technology Without the Capital Footprint At-a-Glance Value Summary

MRI/Ultrasound Fusion Biopsy Advantage	
Financial Advantage	Fewer repeat biopsies » lower overall cost per diagnosis
	Avoids capital investment; pay-per-use model
Technical Advantage	Access to the latest UroNav technology and trained specialists
	3D lesion mapping improves biopsy precision
Clinical Advantage	Higher detection of clinically significant cancer (Gleason 7+)
	Lower complication risk: fewer infections and bleeding events
Operational Efficiency	Streamlined workflow; fewer follow-up biopsies for unclear results
	Supports advanced prostate therapies with better lesion localization

Streamlining the Biopsy Suite: What to Expect

MRI/ultrasound fusion biopsy improves diagnostic accuracy while reducing harm. By targeting only the lesions most suspicious for clinically significant cancer, patients experience fewer cores, fewer complications, and fewer repeat procedures. Better mapping also supports future treatment approaches, such as Cryo therapy.



Conclusion

MRI/ultrasound fusion biopsy is rapidly becoming the new gold standard because it provides superior detection, fewer unnecessary procedures, and improved patient safety. With ForTec Medical's experience and nationwide support, hospitals can seamlessly adopt this technology and immediately enhance their prostate cancer diagnostic program.

Interested in elevating your prostate biopsy program?

Contact your ForTec representative or schedule a clinical demonstration to learn how UroNav fusion biopsy can transform your diagnostic workflow.